Immunotherapy combo shows promise for rare, aggressive breast cancer
NCT ID NCT03515798
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 26 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive form of the disease. About 52 participants will receive either chemo alone or chemo plus pembrolizumab every 3 weeks. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CENTRE Francois Baclesse
Caen, France
-
Centre Georges Francois Leclerc
Dijon, 21079, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Leon Berard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
Clinique de L'Europe
Amiens, France
-
IUCT-Oncopole Institut Claudius Rigaud
Toulouse, France
-
Institut BERGONIE
Bordeaux, France
-
Institut Curie
Paris, France
-
Institut Curie hopital rene huguenin
Saint-Cloud, France
-
Institut Sainte Catherine
Avignon, France
-
Institut de cancérologie de la loire
Saint-Priest-en-Jarez, France
Conditions
Explore the condition pages connected to this study.